Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228088 | 0.83 | — | — | |
| SCHEMBL8866832 | 0.81 | OR51E2 (0.47) | OR51E2LMNAHSD17B10FKBP5CRBN | |
| SCHEMBL19344756 | 0.76 | LMNA (0.35) | OR51E2LMNAHSD17B10 | |
| SCHEMBL11720970 | 0.71 | CRBN (0.50) | OR51E2LMNAHSD17B10FKBP5CRBN | |
| SCHEMBL22908210 | 0.71 | — | — | |
| SCHEMBL5056719 | 0.71 | OR51E2 (0.39) | OR51E2LMNAHSD17B10FKBP5CRBN | |
| SCHEMBL8866835 | 0.69 | OR51E2 (0.43) | OR51E2FKBP5CRBNUHRF1 | |
| SCHEMBL29425335 | 0.69 | — | — | |
| SCHEMBL16738070 | 0.66 | OR51E2 (0.37) | OR51E2FKBP5CRBN | |
| SCHEMBL20100268 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396564-A1 | PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT | EPIGEN BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-01-12 | — | — | US | disclosed |
| EP-2988743-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396564-A1 | PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT | PDXK, RPS6KA6, RPS6KA4 | OR51E2 4252/4885LMNA 4542/4885HSD17B10 3499/4885 |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | PARK7, HTT, SNCA | OR51E2 4101/4885LMNA 1057/4885HSD17B10 3079/4885 |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | TLR2, TLR4, TLR3 | OR51E2 2067/4885LMNA 2891/4885HSD17B10 4095/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | OR51E2 4514/4885LMNA 1289/4885HSD17B10 1771/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | OR51E2 4514/4885LMNA 1289/4885HSD17B10 1771/4885 |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | OR51E2 2067/4885LMNA 2891/4885HSD17B10 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.